Rezultati pretraživanja
  1. prije 2 sata

    DR Horton offering up a pullback opportunity printing a bullish engulfing bar after retracing some of its January rally. One of four swing trade setups from our video today. More here: including setups in and

  2. prije 7 sati

    NEW VIDEO: Stock market swing trade ideas for your watchlist

  3. prije 8 sati

    showed genetically validated targets are 2x as likely to be approved & is 10x as likely to advance as typical pharma. Data also applies to but likely worst case scenario, as ALNY was including its previous generations of delivery now abandoned for GalNAc ESC+

    Prikaži ovu nit
  4. reports before the open tomorrow, Estimize Consensus +0.20 EPS and +3.78M Revs compared to WS -

  5. prije 9 sati
  6. is above its desc rl

  7. prije 21 sat
  8. 4. velj

    triple buy signal, nice setup too.

  9. 4. velj
  10. 3. velj

    Big week ahead 2/3 2/4 2/6 Tecfidera IPR 2/6 SUNFISH 2/7 EAHAD 2/8 wet-AMD 2/8 DME Earnings 2/4 2/5 2/6 2/7

  11. 3. velj

    option volume was 3X normal on Friday with 2,995 contracts. Call volume was 89% and put volume was 11%.

  12. 3. velj

    Information from NASDAQ, will report an outline of the 2019 performance on 6th Feb, 2020.

  13. 2. velj
  14. 29. sij
  15. 28. sij

    newly issued U.S. Patent No. 10,544,418 today for "RNAi Inhibition of Alpha-ENaC Expression." Formerly owned by & - acquired by in IP acquisition in 2015.

  16. 28. sij

    Wow, for RNAi indeed! Bodes well for value of program as well.

  17. 17. sij

    "It would shock me if anybody could write a big enough check to make sense to our shareholders," Arrowhead's CEO told me. Read my latest on the exploding RNAi space of and :

  18. 13. sij

    So it seems the deal is the biggie being announced so far.. amazing Monday is more like fish oil debate Monday instead.. a lot of company updates - rev guidance weak, but lots of trials ongoing guidance also weak. beats etc etc..

  19. 13. sij

    GS Ahead: At a HC investor conference expect potential EPS/revenue pre-announcements from and . Potential data readouts anticipated include LRRK2 data from , registrational data in MTC from and a regulatory update from .

    Prikaži ovu nit
  20. 10. sij

    takes next step toward meeting goal of having 4 approved drugs by YE 20, starts rolling BLA for lumasiran to treat a form of hyperoxaluria The RNAi therapeutic met the primary endpt in a Ph 3 last month:

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.